Sorry, you need to enable JavaScript to visit this website.

Clinical Trials Bridge | XARELTO® (rivaroxaban) HCP

XARELTO® 10 CLINICAL TRIALS ACROSS 9 INDICATIONS

XARELTO® has extensive data in 9 indications: NVAF, PAD post LER, CAD, PAD, VTE prophylaxis for acute medically ill patients, DVT/PE initial treatment, DVT/PE extended treatment, or DVT prophylaxis after hip or knee surgery. To learn more about the clinical trials and studies, please visit the indication-specific clinical trial pages below.

NVAF
CLINICAL TRIALS

PAD POST LER
CLINICAL TRIALS

CAD AND/OR PAD
CLINICAL TRIALS

VTE PROPHYLAXIS
CLINICAL TRIALS

DVT/PE INITIAL TREATMENT
CLINICAL TRIALS

DVT/PE EXTENDED TREATMENT
CLINICAL TRIALS

DVT PROPHYLAXIS
CLINICAL TRIALS

◇For VTE prophylaxis in acutely ill medical patients at risk for thromboembolic complications who are not at high risk of bleeding.

CAD = coronary artery disease; DVT = deep vein thrombosis; LER = lower extremity revascularization; NVAF = nonvalvular atrial fibrillation; PAD = peripheral artery disease; PE = pulmonary embolism; VTE = venous thromboembolism.